drugset / Trial / NCT01188577

Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics

NCT01188577

Phase 1/2 Completed 23 enrolled Amphastar Pharmaceuticals, Inc.
RandomizedCrossoverTriple-blindTreatment

Summary

This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine Inhalation Aerosol USP, an HFA-MDI (E004), using a stable isotope deuterium-labeled epinephrine (epinephrine-d3) to differentiate the administered drug from the endogenous epinephrine, in healthy male and female adult volunteers. The current study is designed for a more thorough evaluation of the E004 Pharmacokinetics. Safety of E004 will also be evaluated, under augmented dose conditions.

Timeline

Start
2010-08
Primary completion
2010-09
Completion
2011-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Epinephrine Other / unclassified 125 ug Inhaled
Subject Epinephrine Other / unclassified 220 ug Inhaled

Indications